Safety considerations with combination therapies for psoriasis
- PMID: 31985309
- DOI: 10.1080/14740338.2020.1722640
Safety considerations with combination therapies for psoriasis
Abstract
Introduction: Psoriasis is a chronic inflammatory skin disease that waxes and wanes, and long-term remission can be difficult to achieve regardless of disease severity. Currently, numerous treatment options are available for psoriasis including steroid and non-steroid topical agents, phototherapy, oral systemic agents, and biologics, with many more therapeutic agents under development.Areas covered: This article will review various combination therapy strategies such as rotational therapy and sequential therapy and describe a variety of safe and effective combination therapies for the treatment of psoriasis. Two or more agents with different mechanisms of action and safety profiles can be used to achieve and/or maintain adequate disease control while minimizing the toxicity of treatments. Combination therapy can also be used when a single agent is not enough for treating recalcitrant disease. Choosing a combination regimen that maximizes safety and efficacy while considering patient usability and compliance can be a challenge.Expert opinion: Given the various treatment options currently available for psoriasis and more agents under development, combination therapy will continue to be a valuable treatment strategy for any patient with psoriasis. It is crucial for clinicians to carefully consider the fine balance between safety and efficacy when combining various therapeutic agents.
Keywords: Psoriasis; biologics; combination therapy; phototherapy; rotational therapy; safety; sequential therapy; systemic therapy.
Similar articles
-
Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456. JAMA Dermatol. 2015. PMID: 25517130 Review.
-
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.J Drugs Dermatol. 2017 Oct 1;16(10):1002-1013. J Drugs Dermatol. 2017. PMID: 29036254
-
Efficacy and safety of treatment modalities for psoriasis.Cutis. 1998 Feb;61(2 Suppl):11-21. Cutis. 1998. PMID: 9787987 Review.
-
Combination therapy in psoriasis: an evidence-based review.Am J Clin Dermatol. 2013 Feb;14(1):9-25. doi: 10.1007/s40257-012-0003-7. Am J Clin Dermatol. 2013. PMID: 23329077 Review.
-
Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.BMC Dermatol. 2019 Jun 21;19(1):9. doi: 10.1186/s12895-019-0087-3. BMC Dermatol. 2019. PMID: 31226985 Free PMC article.
Cited by
-
The role of the adjuvant aesthetic therapy in the lives of patients with psoriatic disease.Postepy Dermatol Alergol. 2022 Dec;39(6):1106-1109. doi: 10.5114/ada.2022.118996. Epub 2022 Aug 23. Postepy Dermatol Alergol. 2022. PMID: 36686008 Free PMC article.
-
Fixed-dose combination of calcipotriene/betamethasone dipropionate foam for the management of mild-to-moderate psoriasis in daily clinical practice: a collection of clinical experiences.Drugs Context. 2024 Oct 9;13:2023-11-5. doi: 10.7573/dic.2023-11-5. eCollection 2024. Drugs Context. 2024. PMID: 39416771 Free PMC article.
-
Co-Delivery of Tacrolimus and Thymoquinone Topically by Nanostructured Lipid Carrier Gel for Enhanced Efficacy Against Psoriasis.AAPS PharmSciTech. 2025 Mar 26;26(4):90. doi: 10.1208/s12249-025-03074-y. AAPS PharmSciTech. 2025. PMID: 40133726
-
Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 25. doi: 10.1007/s00210-025-04334-1. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40560394 Review.
-
Dissolvable hyaluronic acid microneedles loaded with β-Elemene for the treatment of psoriasis.Front Pharmacol. 2022 Nov 18;13:1067051. doi: 10.3389/fphar.2022.1067051. eCollection 2022. Front Pharmacol. 2022. PMID: 36467042 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical